Medicine
Targeted Therapy for BRAF-Mutant Melanoma
Quick fact
About half of all melanomas carry a BRAF V600E mutation, and targeted therapies can shrink tumors in most patients within weeks—but resistance usually develops within a year if used alone.
Why this is interesting
Imagine a cancer that can be turned off like a light switch—but only for a while. What happens when the cancer learns to turn the light back on?
Read the full explanation
Understanding Targeted Therapy for BRAF-Mutant Melanoma
Most cells have a growth control system that tells them when to divide. In BRAF-mutant melanoma, a single letter change in the BRAF gene (V600E) creates a permanently 'on' switch, flooding the cell with division signals. Targeted drugs like vemurafenib are engineered to fit into the BRAF protein's active site, blocking that signal. Imagine a key stuck in a lock that keeps turning the engine—targeted therapy jams the lock. Initially, this works spectacularly: tumors shrink dramatically. But the cancer adapts, finding ways to bypass the blocked gate, which is why doctors combine BRAF inhibitors with MEK inhibitors—to block two steps of the same pathway—slowing the development of resistance.
A deeper explanation
The mechanism is rooted in the MAPK pathway, which relays signals from the cell surface to the nucleus to promote growth. BRAF normally functions as a kinase, activating MEK, which activates ERK. The V600E mutation makes BRAF hyperactive, driving uncontrolled proliferation. Targeted drugs (vemurafenib, dabrafenib) specifically inhibit the mutant BRAF, but not the normal BRAF, leaving normal cells relatively unharmed. However, resistance emerges because cancer cells can reactivate the pathway through secondary mutations, alternative signaling routes, or increased MEK activity. Adding a MEK inhibitor (trametinib) creates a double blockade, reducing the chance of resistance and improving patient outcomes. This approach highlights a core principle: identifying the molecular driver of a cancer enables precision therapy, but evolutionary pressure demands combination strategies.